+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Chemotherapy Induced Nausea and Vomiting Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4620335
  • Report
  • Region: Global
  • Acute Market Reports
1 of 3

FEATURED COMPANIES

  • Baxter Pharmaceuticals
  • Eisai, Inc.
  • GlaxoSmithkline, Plc
  • Helsinn Healthcare
  • Merck & Co. Inc.
  • Pfizer, Inc.
  • MORE
Chemotherapy Induced Nausea and Vomiting Treatment Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026, the global chemotherapy induced nausea and vomiting market was valued at US$ 2,057.4 Mn in 2017, and is expected to reach US$ 3,626.1 Mn by 2026, expanding at a CAGR of 6.5% from 2018 to 2026.

Market Insights
As per the latest research citings of National Cancer Institute, in 2016 there were approximately 15.5 million cancer survivors due to early intervention of chemotherapy. Business analysts predict the rise in survivors to 20.3 million by 2030. The etiology of CINV is not very well understood, however the involvement of the chemo trigger zone and gastrointestinal mucosa have been reported in multiple studies. Chemotherapy induced nausea and vomiting are classified as acute, refractory and delayed. The intensity of CINV depends on the use of drugs in chemotherapy and patient factors. The challenges associated with the antiemetic prescribed for CINV are nonadherence and lack of effective guidelines for CINV treatment. Newer antiemetic drugs such as palonosetron and aprepitant have shown good pharmacokinetic properties in adult cancer patients, still more clinical trials are required for its safety in children.

Serotonin receptor antagonist represents major share in the chemotherapy induced nausea and vomiting treatment market. Excellent pharmacodynamics properties of newer 5HT3 receptor antagonist and availability in oral, intravenous and transdermal patches makes it popular among the physicians treating CINV. Dopamine antagonist have found prominence in treating acute nausea with minimal side effects. NK1 receptor antagonist will project healthy growth during the forecast period on account of its optimum pharmacokinetic properties, and is found effective in the treatment of refractory nausea in patients suffering with chemotherapy induced nausea and vomiting.

North America is the global leader in chemotherapy induced nausea and vomiting treatment market. Domicile of market leaders such as Sanofi-Aventis, Helsinn Healthcare etc., manufacturing CINV drugs and increasing demand for chemotherapy drive the CINV treatment market in North America. Technological advancement in the diagnostic kits results in accurate diagnosis of cancer, thereby enrolling patients on chemotherapy treatment in Europe. Asia Pacific will project excellent growth during the forecast period due to factors such as rising prevalence of cancer and developing healthcare infrastructure. It serves as a lucrative market for generic antiemetic drugs employed for the treatment of chemotherapy induced nausea and vomiting.

The major players steering the chemotherapy induced nausea and vomiting treatment market are Baxter Pharmaceuticals, Eisai, Inc., Helsinn Healthcare, GlaxoSmithkline, Plc, Merck & Co., Inc., ProStrakan, Inc., Pfizer, Inc., Sanofi-Aventis, Solvay Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd.

Key Market Movements:
  • Rising demand for chemotherapy as treatment option in patients suffering with cancer
  • Excellent clinical outcomes of drug combination serotonin receptor antagonist/NK1 receptor antagonist in CINV treatment
  • Affordable reimbursement scenario for generic antiemetic drugs employed for CINV treatment
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Baxter Pharmaceuticals
  • Eisai, Inc.
  • GlaxoSmithkline, Plc
  • Helsinn Healthcare
  • Merck & Co. Inc.
  • Pfizer, Inc.
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Chemotherapy Induced Nausea and Vomiting Treatment Market Portraiture
2.2. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Class, 2017 (US$ Mn)
2.3. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3. Chemotherapy Induced Nausea and Vomiting Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Key Players, 2017

Chapter 4. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class
4.1. Overview
4.2. Serotonin Receptor Antagonist
4.2.1. Ondansetron
4.2.2. Granisetron
4.2.3. Dolasetron
4.2.4. Palonosetron
4.3. Neurokinin NK1 Receptor Antagonist
4.3.1. Aprepitant
4.3.2. Casopitant
4.3.3. Netupitant
4.4. Dopamine Antagonist
4.4.1. Metoclopramide
4.4.2. Prochlorperazine
4.5. Benzodiazepine
4.5.1. Lorazepam
4.6. Others (Corticosteroids, Cannabinoids)

Chapter 5. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography
5.1. Overview
5.2. North America Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.2.1. North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.3.1. Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market Analysis, 2016 – 2026
5.4.1. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.5.1. Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016 – 2026
5.6.1. MEA Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Chemotherapy Induced Nausea and Vomiting Treatment Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Baxter Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Eisai, Inc.
6.3. Helsinn Healthcare
6.4. GlaxoSmithkline, Plc
6.5. Merck & Co. Inc.
6.6. ProStrakan, Inc.
6.7. Pfizer, Inc.
6.8. Sanofi-Aventis
6.9. Solvay Pharmaceuticals, Inc.
6.10. Teva Pharmaceutical Industries Ltd.

List of Figures:
Figure. 1 Chemotherapy Induced Nausea and Vomiting Treatment Market: Research Methodology
Figure. 2 Chemotherapy Induced Nausea and Vomiting Treatment: Market Segmentation
Figure. 3 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2017 (US$ Mn)
Figure. 4 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography, 2017 (US$ Mn)
Figure. 5 Attractive Investment Proposition: by Geography, 2017
Figure. 6 Competitive Analysis: Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Key Players, 2017
Figure. 7 Global Ondansetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 8 Global Granisetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 9 Global Dolasetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 10 Global Palonosetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 11 Global Aprepitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 12 Global Casopitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 13 Global Netupitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 14 Global Metoclopramide Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 15 Global Prochlorperazine Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 16 Global Lorazepam Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 17 Global Other Drug Class Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
Figure. 18 U.S. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 19 Canada Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 20 U.K. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 21 Germany Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 22 Rest of Europe Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 23 China Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 24 Japan Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 25 Rest of Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 26 Brazil Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 27 Mexico Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 28 Rest of Latin America Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 29 GCC Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure. 30 Rest of Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)

List of Tables:
Table 1 Global Chemotherapy Induced Nausea and Vomiting Treatment Market Portraiture
Table 2 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 3 Global Serotonin Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
Table 4 Global Neurokinin NK1 Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
Table 5 Global Dopamine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
Table 6 Global Benzodiazepine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
Table 7 Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
Table 8 North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 9 North America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country, 2016 – 2026 (US$ Mn)
Table 10 Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 11 Europe Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 12 Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 13 Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2015 – 2025 (US$ Mn)
Table 14 Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 15 Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 16 Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 17 Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Market, by Region, 2016 – 2026 (US$ Mn)
Table 18 Baxter Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 19 Eisai, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 20 Helsinn Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 GlaxoSmithkline, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 ProStrakan, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 24 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 25 Sanofi-Aventis: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 26 Solvay Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 27 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Baxter Pharmaceuticals
  • Eisai, Inc.
  • Helsinn Healthcare
  • GlaxoSmithkline, Plc
  • Merck & Co. Inc.
  • ProStrakan, Inc.
  • Pfizer, Inc.
  • Sanofi-Aventis
  • Solvay Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll